What is the fair value of BMY stock?

Our analysis estimates the fair value range for BMY to be between $59.25 and $63.15. The current price is $63.28.

What is the analyst price target for BMY?

The average Wall Street analyst price target for BMY is $65.42. This implies a potential upside of 7.0% from current levels.

Bristol-Myers Squibb (BMY) Stock: Buy, Sell, or Hold?

BMY - Bristol-Myers Squibb Co.

PHARMACEUTICAL PREPARATIONS

$63.28

2.16 (3.53%) ▲

5d: +4.47%

30d: +3.48%

90d: +1.92%

WAIT

LOW Confidence

Protect Your BMY Gains

Analysis Updated: Oct 22, 2026 12:00 AM ET

Earnings: Oct 29, 2026 6d

Smart Money Distribution

Options positioning is turning defensive after a sharp run-up - a pattern consistent with institutional profit-taking. View Scanner →

Signal fired Oct 19, 2026 at $58.83 · last confirmed Oct 20, 2026

Strength: 7.7/10

Get Alerted When BMY Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.

100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading historical data...

💡

Bottom Line:
ℹ️ NEUTRAL: BMY is fairly priced but lacks strong directional signals. At -0.8% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.

See Forward Earnings Fair Value & Price Prediction →

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

Adjust Growth Assumption: 25.0%

0% (Stagnation) 50% (Hyper Growth)

EST. PRICE IN 2031

$122.55

Based on 14.5% avg growth

INTRINSIC VALUE TODAY

$76.09

16.8% Margin of Safety

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 9.5x Exit PE.

View Full DCF Model

In-depth Analysis How we analyze

Valuation Analysis: BMY is currently trading at $63.28, which is considered slightly high relative to its 30-day fair value range of $59.25 to $63.15. The stock's valuation (Forward PE: 9.2) is in line with its historical norms (9.5). Remarkably, the market is currently pricing in an annual earnings decline of 0.8% over the next few years. This pessimistic expectation contrasts with the company's recent 153.1% earnings growth, suggesting potential undervaluation if the company simply maintains stability.

Technical Outlook: Technically, BMY is in a uptrend. The price is approaching resistance at $63.59. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.5% recently.

Market Sentiment: BMY scores 38/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.

Quick Decision Summary

Current Position SLIGHTLY HIGH

Historical Trading Range $59.25 - $63.15

Company Quality Score 44/100 (HOLD)

Volume Confirmation HIGH

Confidence Score 42.9%

Protect Your Profits

Holding BMY? Use our AI-powered strategies to protect your downside while keeping your long-term position.

View Profit Protection Plan

All Signals

BEARISH: Weak technical setup (38/100)
BULLISH: High volume confirmation
BULLISH: Strong upward momentum (+3.5%)
NEUTRAL: Near Wall St target ($65.42)
WARNING: Composite score 44/100 in the bottom quintile — this cohort historically lags the market

Trading Range Analysis

30-Day Trading Range $59.25 - $63.15

Current vs Trading Range SLIGHTLY HIGH

Support & Resistance Levels

Support Level $56.15

Resistance Level $63.59

Current Trend Uptrend

Technical data as of Oct 22, 2026

Fundamental Context

Forward P/E (Next Year Est.) 9.23

Wall Street Target $65.42 (+7.0%)

Revenue Growth (YoY) 5.7%

Earnings Growth (YoY) 153.1%

Profit Margin 18.9%

Valuation Discount vs History -0.8% cheaper

PE vs Historical 9.2 vs 9.5 FAIR

Market-Implied Price Targets If current PE multiple persists

Implied Growth (YoY): -0.8% (market-implied from PE analysis)

1-Year Target $60.63 (-1%)

2-Year Target $60.15 (-2%)

3-Year Target $59.66 (-2%)

3-Yr Target (if PE normalizes) (PE: 9→10) $61.43 (+1%)

3-Year Scenarios Using analyst projected EPS growth

Bull: (PE: 19.9, Growth: 63.3%) $134.07 (+119%)

Base: (SPY PE: 9.2, Growth: 63.3%) $62.29 (+2%)

Bear: (PE: 7.8, Growth: 63.3%) $52.95 (-13%)

📈 Valuation based on Current Earnings

RECOVERY PLAY: Stock looks expensive now (14x PE), but valuation improves significantly next year (9x PE) as earnings recover.

Trailing PE: 13.59 | Current EPS (TTM): $4.54

Bull Case $99.00 (+62%)

Analyst growth 45.9%, PE expands to 14.9

Base Case $90.00 (+47%)

Market implied 45.9%, PE stable at 13.6

Bear Case $41.94 (-31%)

Severe decline -20.0%, PE contracts to 11.6

These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.

💡 Upside Surprise Potential

If earnings stabilize (0% growth), PE could expand from 9.2 to 9.5

Stabilization Target: $62.93 (+3.0%)

PE Expansion Potential: +3.0%

Share & Embed Analysis

Found this analysis useful? Share it with your community or embed the live chart on your blog.

Tweet Reddit

bloggers & journalists: you are free to use our charts with attribution.

Last updated: October 22, 2026 3:30 PM ET
Data refreshes hourly during market hours. Next update: 4:30 PM

🔥 Top Stocks Breaking Out Now

Ticker	Score	Recommendation	Change %

See Full Scanner Results »

Technical Signals Check

Is BMY showing a specific setup today?

RSI Divergence Check TTM Squeeze Check MACD Crossover Check Gamma Walls Check Unusual Activity Check

Insider Activity (6 Months)

Buys

Sells

Net

NEUTRAL

View Insider Activity Scanner

Unlock Insider Activity

See real-time buying/selling by company executives for BMY.

Create Free Account

Already have an account? Log In

Featured in Portfolios

BMY is a key holding in these high-performance investment strategies.

Healthcare Giants Sector • +26.5% Return

View All Strategies

Top Rated Drug Manufacturers - General Stocks

Top-rated stocks in Drug Manufacturers - General by analyst ratings.

Stock	Analyst Consensus	Analyst Target	Tradestie Score
ABBV AbbVie Inc	STRONG BUY 30 analysts	$283	44 HOLD
GILD Gilead Sciences Inc	STRONG BUY 28 analysts	$160	43 HOLD
LLY Eli Lilly and Company	STRONG BUY 31 analysts	$1328	27 SELL
BIIB Biogen Inc	BUY 36 analysts	$244	39 SELL
MRK Merck & Company Inc	STRONG BUY 27 analysts	$158	43 HOLD

ABBV AbbVie Inc

44 HOLD

GILD Gilead Sciences I…

43 HOLD

LLY Eli Lilly and Com…

27 SELL

BIIB Biogen Inc

39 SELL

MRK Merck & Company I…

43 HOLD

Advanced BMY Option Strategies

Professional options setups generated by AI based on today's BMY price and gamma walls.

Iron Condor Bull Call Bear Put Collar

More Analysis for BMY

BMY Technical Chart BMY Price Prediction BMY Earnings Date BMY Investment Advisor BMY Fair Price Analyzer BMY Options Advisor BMY Options Chain BMY Options Analysis BMY Competitors

Compare BMY with Peers

BMY vs MRK
Which one to buy?

BMY vs ABT
Which one to buy?

BMY vs LLY
Which one to buy?

BMY vs ABBV
Which one to buy?

BMY vs AMGN
Which one to buy?

MRK vs BMY

BMY vs JNJ
Winner: JNJ

KALV vs BMY

BMY vs NVS

NVO vs BMY

SCNX vs BMY
Winner: BMY

BMY vs ORGO

TRAW vs BMY
Winner: BMY

ABBV vs BMY

MRSN vs BMY

Create New Comparison View All Competitors

Tradestie